These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 7903868)

  • 21. Different serine and glycine metabolism in patients with schizophrenia receiving clozapine.
    Hons J; Vasatova M; Cermakova E; Doubek P; Libiger J
    J Psychiatr Res; 2012 Jun; 46(6):811-8. PubMed ID: 22502820
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Erythrocyte ketone reductase activity, total plasma haloperidol and acute psychoses].
    Dutoit D; Thomas P; Leroux JM; Vaiga G; Pommery J; Cottencin O; Erb F; Goudemand M
    Encephale; 1995; 21(6):417-24. PubMed ID: 8674466
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Neuroleptic modification of basic schizophrenic disorders].
    Heim M; Morgner J
    Psychiatr Neurol Med Psychol (Leipz); 1987 May; 39(5):274-80. PubMed ID: 2888144
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Plasma homovanillic acid levels and therapeutic outcome in schizophrenics: comparisons of neuroleptic-naive first-episode patients and patients with disease exacerbation due to neuroleptic discontinuance.
    Akiyama K; Tsuchida K; Kanzaki A; Ujike H; Hamamura T; Kondo K; Mutoh S; Miyanagi K; Kuroda S; Otsuki S
    Biol Psychiatry; 1995 Nov; 38(10):639-48. PubMed ID: 8555375
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The relationship between negative symptoms of schizophrenia and extrapyramidal side effects with haloperidol and olanzapine.
    Allan ER; Sison CE; Alpert M; Connolly B; Crichton J
    Psychopharmacol Bull; 1998; 34(1):71-4. PubMed ID: 9564201
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Long-term therapy of chronic schizophrenic patients with haloperidol decanoate].
    Roncoroni D
    Psychiatr Prax; 1984 Mar; 11(2):56-8. PubMed ID: 6144121
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neuroleptic effects on platelet aggregation: a study in normal volunteers and schizophrenics.
    Dinan TG
    Psychol Med; 1987 Nov; 17(4):875-81. PubMed ID: 2893407
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Negative correlation between alpha-1-acid-glycoprotein plasma level and response to haloperidol in the acute treatment of schizophrenia.
    Levinson I; Levine S
    Biol Psychiatry; 1995 Aug; 38(3):198-200. PubMed ID: 7578667
    [No Abstract]   [Full Text] [Related]  

  • 29. [Zotepine: treatment of schizophrenic patients with predominantly negative symptoms. A double-blind study vs. haloperidol].
    Barnas C; Stuppäck CH; Miller C; Haring C; Sperner-Unterweger B; Fleischhacker WW
    Fortschr Neurol Psychiatr; 1991 Sep; 59 Suppl 1():36-40. PubMed ID: 1683338
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Subjective response to neuroleptics in schizophrenia.
    Awad AG
    Schizophr Bull; 1993; 19(3):609-18. PubMed ID: 7901897
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fluphenazine activity and antipsychotic response.
    Hitzemann RJ; Garver DL; Mavroidis M; Hirschowitz J; Zemlan FP
    Psychopharmacology (Berl); 1986; 90(2):270-3. PubMed ID: 3097710
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serine and glycine metabolism in schizophrenic patients.
    Lucca A; Cortinovis S; Lucini V
    Prog Neuropsychopharmacol Biol Psychiatry; 1993 Nov; 17(6):947-53. PubMed ID: 8278604
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Metabolism of an ingested serine load in psychotic and nonpsychotic subjects.
    Wilcox J; Waziri R; Sherman A; Mott J
    Biol Psychiatry; 1985 Jan; 20(1):41-9. PubMed ID: 3917310
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Alterations of gait parameters under external cueing in schizophrenic patients: a switch study].
    Putzhammer A; Perfahl M; Pfeiff L; Broll K; Hess L; Ibach B
    Psychiatr Prax; 2004 Nov; 31 Suppl 1():S164-6. PubMed ID: 15570541
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Beacon-like/ubiquitin-5-like immunoreactivity is highly expressed in human hypothalamus and increased in haloperidol-treated schizophrenics and a rat model of schizophrenia.
    Bernstein HG; Lendeckel U; Dobrowolny H; Stauch R; Steiner J; Grecksch G; Becker A; Jirikowski GF; Bogerts B
    Psychoneuroendocrinology; 2008 Apr; 33(3):340-51. PubMed ID: 18191906
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Double-blind comparison of haloperidol decanoate and fluphenazine decanoate effectiveness, side-effects, dosage and serum levels during a six months' treatment for relapse prevention.
    Kissling W; Möller HJ; Walter K; Wittmann B; Krueger R; Trenk D
    Pharmacopsychiatry; 1985 May; 18(3):240-5. PubMed ID: 4011672
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neuroleptic drug effect on plasma dopamine-beta-hydroxylase in schizophrenia.
    Baron M; Gruen R; Levitt M; Kane J
    Neuropsychobiology; 1982; 8(6):312-4. PubMed ID: 6131392
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Do neuroleptics impair learning in schizophrenic patients?
    Cutmore TR; Beninger RJ
    Schizophr Res; 1990; 3(3):173-86. PubMed ID: 1980612
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dysphoric response to neuroleptics as a predictor of treatment outcome with schizophrenics. A comparative study of haloperidol versus mesoridazine.
    White K; Busk J; Eaton E; Gomez G; Razani J; Sloane RB
    Int Pharmacopsychiatry; 1981; 16(1):34-8. PubMed ID: 6117536
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Relation of plasma glycine, serine, and homocysteine levels to schizophrenia symptoms and medication type.
    Neeman G; Blanaru M; Bloch B; Kremer I; Ermilov M; Javitt DC; Heresco-Levy U
    Am J Psychiatry; 2005 Sep; 162(9):1738-40. PubMed ID: 16135636
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.